Compare Biogen Inc (BIIB) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Biogen Inc trades at $207.48 (market cap $30.13B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.76. The key difference: Biogen Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| BIIB | TMF | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $44.14 |
52-Week Low | $128.93 | $30.59 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.76, up 0.38% today, but technical indicators are predominantly bearish with moving averages signaling sell. Key financial ratios like P/E and P/S are unavailable, and the fund's leveraged structure amplifies volatility. Recent news highlights significant long-term losses, with a $10,000 investment five years ago now worth about $1,527, underscoring the risks of daily rebalancing.
The outlook for TMF is highly speculative, offering potential gains if long-term Treasury yields decline, but it carries extreme risk due to leverage decay and interest rate sensitivity. Investors should avoid long-term holdings, as the fund is suited only for short-term traders who can manage amplified losses. Macroeconomic shifts in bond markets remain the primary driver of performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
